I uge 24 var antallet af ASAS 20 responders 15/ 78 (19%) i placebogruppen og 123/ 201 (61%) i gruppen, der fik 5 mg/ kg infliximab (p < 0, 001).
At week 24, the number of ASAS 20 responders was 15/ 78 (19%) in the placebo group, and 123/ 201 (61%) in the 5 mg/ kg infliximab group (p < 0.001).